Avaliação do efeito do Resveratrol sobre a modulação da doença hepática gordurosa não alcoólica em camundongos obesos: participação da via de sinalização de PTEN/MAF1

Abstract

Non-alcoholic Fatty acid disease (NAFLD), being these alterations considered obesity clinical pathological components. The search for natural therapeutic products have been the focus of several studies, and resveratrol, a natural polyphenol, has demonstrated its beneficial effects in lipid metabolism, cardiovascular diseases and cancers. Thus, the present study aimed to evaluate the resveratrol effects in mice with NAFLD induced by high-fat diet. Swiss male mice were divided into 4 groups (Standard diet, Standard diet + resveratrol, High-fat diet and High-fat diet + resveratrol) for eight weeks. Resveratrol was administered by gavage for 4 weeks a dose of 30mg / kg.. In the last treatment week, animals were submitted to insulin sensitivity and glucose tolerance tests. The animals were then killed and plasma total cholesterol, triglycerides, GOT and GPT levels were measured. Epididymal, and liver were weighted and stored for posterior molecular analysis. Lipid accumulation was evaluated by histological analysis (H&E and Sudan IV staining). Liver mRNA expression of key genes (PTEN, MAF1, NNMT and RXRα) was assessed by RT-PCR. The main findings show that resveratrol decreased epidydimal adipose tissue weight, improved glucose metabolism (via increased insulin sensitivity and glucose tolerance), decreased total cholesterol, triglycerides and GPT levels and lipid accumulation in the liver. Increased PTEN, MAF1 and NNMT expression were observed, while RXRα was decreased by resveratrol. It was concluded that obese mice (HFD), treated with resveratrol for 4 weeks, showed hepatic conditions, due to a significant reduction of fat content in hepatocytes due to the probable modulation of MAF1. Keywords: Metabolic syndrome, hepatic steatosis, resveratrol.